drugset / Trial / NCT04921904
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
NaSingle-groupOpen-labelTreatment
Summary
CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.
Timeline
- Start
- 2021-06-11
- Primary completion
- 2024-12-31
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |